Preparation and activities of macromolecule conjugates of the CCR5 antagonist maraviroc

ACS Medicinal Chemistry Letters

Volumn 5, Issue 2, 2014, Pages 133-137

  Asano, Shigehiro ^a   Gavrilyuk, Julia ^a   Burton, Dennis R ^a   Barbas, Carlos F ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

CCR5 antagonist; chemically programmed antibody; Maraviroc; PEGylation

Indexed keywords

MARAVIROC;

ARTICLE; BINDING SITE; CONFORMATIONAL TRANSITION; DRUG CONJUGATION; DRUG SOLUBILITY; GRAFT VERSUS HOST REACTION; HELA CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; IMMUNOGENICITY; MACROMOLECULE; MEMBRANE FUSION; PATIENT COMPLIANCE; PLASMA HALF LIFE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STRUCTURE ACTIVITY RELATION; TARGET CELL;

EID: 84894107640     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml400370w     Document Type: Article

References (36)

1. Mehellou, Y.; De Clercq, E. Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go? J. Med. Chem. 2010, 53, 521-38
2. Deng, H.; Liu, R.; Ellmeier, W.; Choe, S.; Unutmaz, D.; Burkhart, M.; Di Marzio, P.; Marmon, S.; Sutton, R. E.; Hill, C. M.; Davis, C. B.; Peiper, S. C.; Schall, T. J.; Littman, D. R.; Landau, N. R. Identification of a major co-receptor for primary isolates of HIV-1 Nature 1996, 381, 661-6 (Pubitemid 26197679)
3. Dragic, T.; Litwin, V.; Allaway, G. P.; Martin, S. R.; Huang, Y.; Nagashima, K. A.; Cayanan, C.; Maddon, P. J.; Koup, R. A.; Moore, J. P.; Paxton, W. A. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 Nature 1996, 381, 667-73 (Pubitemid 26197680)
4. Doranz, B. J.; Berson, J. F.; Rucker, J.; Doms, R. W. Chemokine receptors as fusion cofactors for human immunodeficiency virus type 1 (HIV-1) Immunol. Res. 1997, 16, 15-28 (Pubitemid 27129627)
5. Broder, C. C.; Collman, R. G. Chemokine receptors and HIV J. Leukocyte Biol. 1997, 62, 20-9 (Pubitemid 27321735)
6. Bredeek, U. F.; Harbour, M. J. CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1 Eur. J. Med. Res. 2007, 12, 427-34 (Pubitemid 350011455)
7. Dorr, P.; Perros, M. CCR5 inhibitors in HIV-1 therapy Expert Opin. Drug Discovery 2008, 3, 1345-61
8. Latinovic, O.; Kuruppu, J.; Davis, C.; Le, N.; Heredia, A. Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc Clin. Med. Ther. 2009, 1, 1497-1510
9. Poveda, E.; Paredes, R.; Moreno, S.; Alcami, J.; Cordoba, J.; Delgado, R.; Gutierrez, F.; Llibre, J. M.; Garcia Deltoro, M.; Hernandez-Quero, J.; Pulido, F.; Iribarren, J. A.; Garcia, F. Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists AIDS Rev. 2012, 14, 208-17
10. Reshef, R.; Luger, S. M.; Hexner, E. O.; Loren, A. W.; Frey, N. V.; Nasta, S. D.; Goldstein, S. C.; Stadtmauer, E. A.; Smith, J.; Bailey, S.; Mick, R.; Heitjan, D. F.; Emerson, S. G.; Hoxie, J. A.; Vonderheide, R. H.; Porter, D. L. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease N. Engl. J. Med. 2012, 367, 135-45
11. Alonzo, F., 3rd; Kozhaya, L.; Rawlings, S. A.; Reyes-Robles, T.; DuMont, A. L.; Myszka, D. G.; Landau, N. R.; Unutmaz, D.; Torres, V. J. CCR5 is a receptor for Staphylococcus aureus leukotoxin ED Nature 2013, 493, 51-5
12. Rader, C.; Sinha, S. C.; Popkov, M.; Lerner, R. A.; Barbas, C. F., 3rd Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 5396-400 (Pubitemid 36542716)
13. Popkov, M.; Rader, C.; Gonzalez, B.; Sinha, S. C.; Barbas, C. F., 3rd. Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector Int. J. Cancer 2006, 119, 1194-207 (Pubitemid 44116929)
14. Gavrilyuk, J. I.; Wuellner, U.; Barbas, C. F., 3rd Beta-lactam-based approach for the chemical programming of aldolase antibody 38C2 Bioorg. Med. Chem. Lett. 2009, 19, 1421-4
15. Wuellner, U.; Gavrilyuk, J. I.; Barbas, C. F., 3rd Expanding the concept of chemically programmable antibodies to RNA aptamers: chemically programmed biotherapeutics Angew. Chem., Int. Ed. Engl. 2010, 49, 5934-7
16. Gavrilyuk, J.; Uehara, H.; Otsubo, N.; Hessell, A.; Burton, D. R.; Barbas, C. F., 3rd Potent inhibition of HIV-1 entry with a chemically programmed antibody aided by an efficient organocatalytic synthesis ChemBioChem 2010, 11, 2113-8
17. Huang, H.; Lai, J. Y.; Do, J.; Liu, D.; Li, L.; Del Rosario, J.; Doppalapudi, V. R.; Pirie-Shepherd, S.; Levin, N.; Bradshaw, C.; Woodnutt, G.; Lappe, R.; Bhat, A. Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2011, 17, 1001-11
18. Hayakawa, M.; Toda, N.; Carrillo, N.; Thornburg, N. J.; Crowe, J. E., Jr.; Barbas, C. F., 3rd A chemically programmed antibody is a long-lasting and potent inhibitor of influenza neuraminidase ChemBioChem 2012, 13, 2191-5
19. Sato, S.; Inokuma, T.; Otsubo, N.; Burton, D. R.; Barbas, C. F., 3rd. Chemically Programmed Antibodies as HIV-1 Attachment Inhibitors ACS Med. Chem. Lett. 2013, 4, 460-465
20. Wagner, J.; Lerner, R. A.; Barbas, C. F., 3rd Efficient aldolase catalytic antibodies that use the enamine mechanism of natural enzymes Science 1995, 270, 1797-800 (Pubitemid 26007222)
21. Zhong, G.; Lerner, R. A.; Barbas, I. C. Broadening the Aldolase Catalytic Antibody Repertoire by Combining Reactive Immunization and Transition State Theory: New Enantio- and Diastereoselectivities Angew. Chem., Int. Ed. Engl. 1999, 38, 3738-3741 (Pubitemid 30022002)
22. Shabat, D.; Rader, C.; List, B.; Lerner, R. A.; Barbas, C. F., 3rd. Multiple event activation of a generic prodrug trigger by antibody catalysis Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 6925-30 (Pubitemid 29274986)
23. Brinckerhoff, L. H.; Kalashnikov, V. V.; Thompson, L. W.; Yamshchikov, G. V.; Pierce, R. A.; Galavotti, H. S.; Engelhard, V. H.; Slingluff, C. L., Jr. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines Int. J. Cancer 1999, 83, 326-34 (Pubitemid 29455755)
24. Cheng, T. L.; Chen, B. M.; Chan, L. Y.; Wu, P. Y.; Chern, J. W.; Roffler, S. R. Poly(ethylene glycol) modification of beta-glucuronidase-antibody conjugates for solid-tumor therapy by targeted activation of glucuronide prodrugs Cancer Immunol. Immunother. 1997, 44, 305-15 (Pubitemid 27364610)
25. Chaffee, S.; Mary, A.; Stiehm, E. R.; Girault, D.; Fischer, A.; Hershfield, M. S. IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency J. Clin. Invest. 1992, 89, 1643-51
26. Wang, Y. S.; Youngster, S.; Grace, M.; Bausch, J.; Bordens, R.; Wyss, D. F. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications Adv. Drug Delivery Rev. 2002, 54, 547-70 (Pubitemid 34618512)
27. Greenwald, R. B.; Pendri, A.; Conover, C.; Gilbert, C.; Yang, R.; Xia, J. Drug delivery systems. 2. Camptothecin 20-O-poly(ethylene glycol) ester transport forms J. Med. Chem. 1996, 39, 1938-40 (Pubitemid 26157293)
28. Pepinsky, R. B.; Lee, W. C.; Cornebise, M.; Gill, A.; Wortham, K.; Chen, L. L.; Leone, D. R.; Giza, K.; Dolinski, B. M.; Perper, S.; Nickerson-Nutter, C.; Lepage, D.; Chakraborty, A.; Whalley, E. T.; Petter, R. C.; Adams, S. P.; Lobb, R. R.; Scott, D. M. Design, synthesis, and analysis of a polyethelene glycol-modified (PEGylated) small molecule inhibitor of integrin {alpha}4{beta}1 with improved pharmaceutical properties J. Pharmacol. Exp. Ther. 2005, 312, 742-50 (Pubitemid 40189574)
29. Kondru, R.; Zhang, J.; Ji, C.; Mirzadegan, T.; Rotstein, D.; Sankuratri, S.; Dioszegi, M. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists Mol. Pharmacol. 2008, 73, 789-800 (Pubitemid 351397884)
30. Sinha, S. C.; Das, S.; Li, L. S.; Lerner, R. A.; Barbas, C. F., 3rd. Preparation of integrin alpha(v)beta3-targeting Ab 38C2 constructs Nat. Protoc. 2007, 2, 449-56 (Pubitemid 47040060)
31. Wood, A.; Armour, D. The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS Prog. Med. Chem. 2005, 43, 239-71
32. Yamaoka, T.; Tabata, Y.; Ikada, Y. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice J. Pharm. Sci. 1994, 83, 601-6 (Pubitemid 24222392)
33. Bailon, P. B. W. Polyethylene glycol-conjugated pharmaceutical proteins Pharm. Sci. Technol. Today 1998, 1, 352-356
34. Rudnick, S. I.; Adams, G. P. Affinity and avidity in antibody-based tumor targeting Cancer Biother. Radiopharm. 2009, 24, 155-61
35. Popkov, M.; Gonzalez, B.; Sinha, S. C.; Barbas, C. F., 3rd. Instant immunity through chemically programmable vaccination and covalent self-assembly Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 4378-83
36. Gavrilyuk, J.; Ban, H.; Uehara, H.; Sirk, S. J.; Saye-Francisco, K.; Cuevas, A.; Zablowsky, E.; Oza, A.; Seaman, M. S.; Burton, D. R.; Barbas, C. F., 3rd. Antibody conjugation approach enhances breadth and potency of neutralization of anti-HIV-1 antibodies and CD4-IgG J. Virol. 2013, 87, 4985-93